BACKGROUND: Incidence reports for pediatric lymphoma and lymphoid leukemia in Hispanic subpopulations in the United States are rare. The authors hypothesized that Florida's Hispanic children would have higher risks of lymphoma and lymphoid leukemia compared with non-Hispanic white children. METHODS: All cases of lymphoid leukemia, Hodgkin, non-Hodgkin, and Burkitt lymphoma (SEER International Classification of Diseases for Oncology codes) in children (< 15 years) in the Florida Cancer Data System (FCDS) from 1985 to 1997 were studied. Cases were classified as: 1) white, 2) Hispanic, or 3) black, and stratified by age. Age-adjusted rates for the three race-ethnic groups were calculated. Rates for Hispanics and blacks were compared with whites as standardized rate ratios (SRR) with 95% confidence intervals. RESULTS: Seven hundred thirty-one incident cases of pediatric lymphoma and 1231 cases of lymphoid leukemia were identified during the study period. For children with lymphoma, the SRR for Hispanics was 1.32 (95% CI, 1.20-1.44), and for blacks, the SRR was 0.68 (95% CI, 0.63-0.72. For lymphoid leukemia, the SRR for Hispanics was 1.29 (95% CI, 1.28-1.30), and for blacks, the SRR was 0.55 (95% CI, 0.54-0.56). Similar rates were found for the Hodgkin and non-Hodgkin subgroups. CONCLUSIONS: Incidences of Hodgkin and non-Hodgkin lymphoma were significantly higher in Florida's Hispanic children, with 30% increased relative risks, compared with whites. Black children had significantly decreased incidences and risk. Results for lymphoid leukemia were similar. Incidence of lymphoma in Florida's Hispanic children (primarily Cuban and Central American origin) differed from similar reports from Texas and California, where Hispanics are primarily of Mexican origin. Copyright 2001 American Cancer Society.
BACKGROUND: Incidence reports for pediatric lymphoma and lymphoid leukemia in Hispanic subpopulations in the United States are rare. The authors hypothesized that Florida's Hispanic children would have higher risks of lymphoma and lymphoid leukemia compared with non-Hispanic white children. METHODS: All cases of lymphoid leukemia, Hodgkin, non-Hodgkin, and Burkitt lymphoma (SEER International Classification of Diseases for Oncology codes) in children (< 15 years) in the Florida Cancer Data System (FCDS) from 1985 to 1997 were studied. Cases were classified as: 1) white, 2) Hispanic, or 3) black, and stratified by age. Age-adjusted rates for the three race-ethnic groups were calculated. Rates for Hispanics and blacks were compared with whites as standardized rate ratios (SRR) with 95% confidence intervals. RESULTS: Seven hundred thirty-one incident cases of pediatric lymphoma and 1231 cases of lymphoid leukemia were identified during the study period. For children with lymphoma, the SRR for Hispanics was 1.32 (95% CI, 1.20-1.44), and for blacks, the SRR was 0.68 (95% CI, 0.63-0.72. For lymphoid leukemia, the SRR for Hispanics was 1.29 (95% CI, 1.28-1.30), and for blacks, the SRR was 0.55 (95% CI, 0.54-0.56). Similar rates were found for the Hodgkin and non-Hodgkin subgroups. CONCLUSIONS: Incidences of Hodgkin and non-Hodgkinlymphoma were significantly higher in Florida's Hispanic children, with 30% increased relative risks, compared with whites. Black children had significantly decreased incidences and risk. Results for lymphoid leukemia were similar. Incidence of lymphoma in Florida's Hispanic children (primarily Cuban and Central American origin) differed from similar reports from Texas and California, where Hispanics are primarily of Mexican origin. Copyright 2001 American Cancer Society.
Authors: Eric J Chow; Susan E Puumala; Beth A Mueller; Susan E Carozza; Erin E Fox; Scott Horel; Kimberly J Johnson; Colleen C McLaughlin; Peggy Reynolds; Julie Von Behren; Logan G Spector Journal: Cancer Date: 2010-06-15 Impact factor: 6.860
Authors: María Luisa Pérez-Saldivar; Arturo Fajardo-Gutiérrez; Roberto Bernáldez-Ríos; Armando Martínez-Avalos; Aurora Medina-Sanson; Laura Espinosa-Hernández; José de Diego Flores-Chapa; Raquel Amador-Sánchez; José Gabriel Peñaloza-González; Francisco Javier Alvarez-Rodríguez; Victoria Bolea-Murga; Janet Flores-Lujano; María Del Carmen Rodríguez-Zepeda; Roberto Rivera-Luna; Elisa María Dorantes-Acosta; Elva Jiménez-Hernández; Martha Alvarado-Ibarra; Martha Margarita Velázquez-Aviña; José Refugio Torres-Nava; David Aldebarán Duarte-Rodríguez; Rogelio Paredes-Aguilera; María de Los Ángeles Del Campo-Martínez; Rocío Cárdenas-Cardos; Paola Hillary Alamilla-Galicia; Vilma Carolina Bekker-Méndez; Manuel Carlos Ortega-Alvarez; Juan Manuel Mejia-Arangure Journal: BMC Cancer Date: 2011-08-17 Impact factor: 4.430
Authors: Juan Manuel Mejía-Aranguré; Miguel Bonilla; Rodolpho Lorenzana; Servando Juárez-Ocaña; Gladys de Reyes; María Luisa Pérez-Saldivar; Guadalupe González-Miranda; Roberto Bernáldez-Ríos; Antonio Ortiz-Fernández; Manuel Ortega-Alvarez; María del Carmen Martínez-García; Arturo Fajardo-Gutiérrez Journal: BMC Cancer Date: 2005-04-04 Impact factor: 4.430
Authors: Janet Flores-Lujano; David Aldebarán Duarte-Rodríguez; Elva Jiménez-Hernández; Jorge Alfonso Martín-Trejo; Aldo Allende-López; José Gabriel Peñaloza-González; María Luisa Pérez-Saldivar; Aurora Medina-Sanson; José Refugio Torres-Nava; Karina Anastacia Solís-Labastida; Luz Victoria Flores-Villegas; Rosa Martha Espinosa-Elizondo; Raquel Amador-Sánchez; Martha Margarita Velázquez-Aviña; Laura Elizabeth Merino-Pasaye; Nora Nancy Núñez-Villegas; Ana Itamar González-Ávila; María de Los Ángeles Del Campo-Martínez; Martha Alvarado-Ibarra; Vilma Carolina Bekker-Méndez; Rocío Cárdenas-Cardos; Silvia Jiménez-Morales; Roberto Rivera-Luna; Haydee Rosas-Vargas; Norma C López-Santiago; Angélica Rangel-López; Alfredo Hidalgo-Miranda; Elizabeth Vega; Minerva Mata-Rocha; Omar Alejandro Sepúlveda-Robles; José Arellano-Galindo; Juan Carlos Núñez-Enríquez; Juan Manuel Mejía-Aranguré Journal: Front Public Health Date: 2022-09-14
Authors: Laura Andrea Rodriguez-Villamizar; Marcela Pilar Rojas Díaz; Lizbeth Alexandra Acuña Merchán; Feisar Enrique Moreno-Corzo; Paula Ramírez-Barbosa Journal: BMC Cancer Date: 2020-01-20 Impact factor: 4.430